Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
REGN-9933 by Regeneron Pharmaceuticals for Venous Thromboembolism: Likelihood of Approval
REGN-9933 is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Venous Thromboembolism. According to GlobalData, Phase...